Vgamma9 Vdelta2 T cell receptor (Vgamma9Vdelta2 TCR)

The Vgamma9 Vdelta2 T cell receptor (Vγ9Vδ2 TCR) is the predominant gamma-delta (γδ) T cell receptor found in human peripheral blood, typically accounting for the vast majority of the circulating γδ T cell population. Unlike conventional alpha-beta (αβ) TCRs, the Vγ9Vδ2 TCR recognizes antigens in a Major Histocompatibility Complex (MHC)-independent manner, specifically responding to small non-peptidic phosphorylated metabolites known as phosphoantigens (PAgs). This recognition process is uniquely mediated by the butyrophilin family proteins, BTN3A1 and BTN2A1, which act as molecular sensors for intracellular PAg levels and undergo conformational changes to activate the receptor. In disease states such as cancer or certain infections, dysregulation of the mevalonate pathway leads to the accumulation of PAgs like isopentenyl pyrophosphate (IPP), which triggers Vγ9Vδ2 T cell activation, proliferation, and potent cytotoxic effector functions. Therapeutic strategies targeting this receptor include the use of aminobisphosphonates (e.g., zoledronic acid) to indirectly increase PAg levels, as well as novel bispecific antibodies (e.g., LAVA-051) and BTN3A1-targeting antibodies (e.g., ICT01) designed to directly engage and activate Vγ9Vδ2 T cells for anti-tumor immunity. These cells are particularly attractive for immunotherapy due to their natural ability to infiltrate tumors and their lack of MHC restriction, which reduces the risk of graft-versus-host disease in allogeneic settings.

Other names

Vgamma9Vdelta2 TCRVγ9Vδ2 TCRVg9Vd2 TCRTCR Vgamma9 Vdelta2TRGV9/TRDV2 receptorT-cell receptor gamma 9 delta 2

Indirect activation via mevalonate pathway inhibition leading to isopentenyl pyrophosphate (IPP) accumulation; direct agonism via TCR-binding bispecific antibodies; and activation via modulation of the BTN3A1/BTN2A1 presenting complex.